Averaging <3637 steps/day during the first week of wearable cardioverter defibrillator use was associated with a higher risk of shock for sustained VT/VF (OR 4.29; 95% CI 2.58-7.15; P<0.001).
Cohort (n=4,057)
Does lower physical activity predict sustained VT/VF requiring emergent defibrillation in patients with EF ≤35% wearing a WCD?
Lower average daily step counts during the first week of wearable cardioverter defibrillator use strongly predict the occurrence of sustained VT/VF requiring defibrillation.
Odds Ratio: 4.29 (95% CI 2.58–7.15)
p-value: p=< .001
INTRODUCTION: The utility of accelerometer-based activity data to identify patients at risk of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) has not previously been investigated. The aim of the current study was to determine whether physical activity is associated with manifesting spontaneous sustained VT/VF requiring emergent defibrillation in patients with an ejection fraction of ≤35%. METHODS: Patients consecutively prescribed a wearable cardioverter defibrillator (WCD) from April 2015 to May 2018 were included. Shock data and 4 weeks of physical activity data, beginning with the first week of WCD wear, were analyzed. RESULTS: Based on the ROC curve outcome generated from 4057 patients, average daily step count during the first week accurately predicted those patients with sustained VT/VF compared to those without (shocked (n = 81) vs nonshocked (n = 3976) area under the curve, c-index = 0.71, 95% CI = 0.65-0.77, P < .001). An average cutoff of 3637 daily steps during week 1 separated the groups. Patients who averaged fewer than 3637 steps per day during the first week of WCD use were 4.3 times more likely to experience a shock than those who walked more than 3637 steps per day (OR = 4.29, 95% CI = 2.58-7.15, P < .001). DISCUSSION: Average daily step counts are lower in WCD patients who manifest spontaneous VT/VF. Whether these findings represent a causal or correlational relationship, future studies to encourage a minimum daily step count in high-risk patients may impact the incidence of sustained VT/VF.
Burch et al. (Mon,) conducted a cohort in Ejection fraction ≤35% requiring a wearable cardioverter defibrillator (n=4,057). Average daily step count < 3637 vs. Average daily step count > 3637 was evaluated on Sustained VT/VF requiring emergent defibrillation (shock) (OR 4.29, 95% CI 2.58-7.15, p=< .001). Averaging <3637 steps/day during the first week of wearable cardioverter defibrillator use was associated with a higher risk of shock for sustained VT/VF (OR 4.29; 95% CI 2.58-7.15; P<0.001).